ResApp Health, an Australian company developing digital healthcare solutions for respiratory conditions, recently reported additional preliminary positive results of its adult clinical trial assessing the company’s app for the diagnosis of different lung diseases, including chronic obstructive pulmonary fibrosis (COPD). According to a ResApp press release, the results showed that the…
A new research study suggests that high indoor temperatures could worsen the symptoms of chronic obstructive pulmonary disease (COPD), particularly in homes with high levels of air pollutants. Johns Hopkins University researchers conducted a longitudinal study including 69 patients with moderate-to-severe COPD during the hottest days of the year. The results of…
A component of red wine and grapes, resveratrol, was seen to halt the pathogen-induced inflammation common in respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. The study, “Resveratrol suppresses NTHi-induced inflammation via up-regulation of the negative regulator MyD88 short,” was published in the online…
Researchers at Canada’s University of British Columbia (UBC) determined that despite a decline in smoking rates, there will be an epidemic of chronic obstructive pulmonary disease (COPD) over the next two decades, with the potential to overwhelm healthcare systems. The report with the predictions was published in the American Journal of…
The benefits of physical activity are widely accepted by scientists and doctors today, with effects observed in weight control, as well as mood and mental health. Now research is showing that increased physical activity among patients with chronic obstructive pulmonary disease (COPD) reduces their risk of anxiety and depression. Results from…
Positive results from a real-world study were recently presented evaluating the effectiveness of the Aerobika Oscillating PEP nondrug device in reducing chronic obstructive pulmonary disease (COPD) exacerbations. Trudell Medical International presented the results of the study at the European Respiratory Society (ERS) International Congress Sept. 3-7 in London. Trudell…
GlaxoSmithKline (GSK) recently presented data showing that its combination drug Relvar Ellipta (fluticasone furoate and vilanterol) causes a statistically significant reduction in the rate of severe lung exacerbations in patients in the Salford Lung Study (SLS), which assessed the safety and effectiveness of the drug in patients with chronic obstructive pulmonary disease (COPD).
Royal Philips is sponsoring the documentary “COPD: Highly Illogical – Remembering Leonard Nimoy,” a tribute that aims to educate viewers about chronic obstructive pulmonary disease (COPD) through the personal journey of the “Star Trek” star while also providing the latest information about available treatments. The documentary is produced by Nimoy’s daughter, Julie Nimoy, and…
Boehringer Ingelheim recently held a 2nd respiratory forum that focused on the growing problem of lung disease across the Middle East and North Africa, and served as a platform for specialists from those regions and Europe to discuss the clinical management and diagnosis of these diseases, and future challenges in controlling their prevalence. The theme for…
PN Medical and Orbita announced they have formed a partnership to leverage Orbita’s next-generation digital platform with its own products, designed to enable clinicians to better monitor and support patients with chronic conditions like chronic obstructive pulmonary disease (COPD), hypertension, and congestive heart failure. “In 1980, we were first to…
Get regular updates to your inbox.